Consun Pharmaceutical Group Limited provided consolidated earnings guidance for the six months ended June 30, 2014. The company expected that the group would record a significant increase in net profit for the six months ended June 30, 2014 as compared with that for the six months ended June 30, 2013, which was primarily attributable to the continued growth of sales of the Group's kidney medicines, contrast medium and other medicines during the period, which increased by more than 30% as compared with the corresponding period of last year, and the interest income of approximately RMB 12,000,000 earned from placing the proceeds of the company's initial public offering of shares on the Stock Exchange on December 19, 2013 at banks temporarily during the period.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6.41 HKD | -2.29% | -2.14% | +34.38% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+34.38% | 692M | |
+15.88% | 42.79B | |
+22.20% | 22.81B | |
+15.74% | 15.04B | |
+17.78% | 14.49B | |
+51.02% | 12.65B | |
-11.45% | 6.74B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+14.55% | 5.47B |
- Stock Market
- Equities
- 1681 Stock
- News Consun Pharmaceutical Group Limited
- Consun Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2014